PMID- 32118071
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Electronic)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in 
      Healthy Dogs.
PG  - 51
LID - 10.3389/fvets.2020.00051 [doi]
LID - 51
AB  - Objective: To determine the safety and tolerability of escalating doses of three 
      cannabis oil formulations, containing predominantly CBD, THC, or CBD and THC 
      (1.5:1) vs. placebo in dogs. Design: Randomized, placebo-controlled, blinded, 
      parallel study. Animals: Twenty healthy Beagle dogs (10 males, 10 females). 
      Methods: Dogs were randomly assigned to one of five treatment groups (n = 4 dogs 
      per group balanced by sex): CBD-predominant oil, THC-predominant oil, 
      CBD/THC-predominant oil (1.5:1), sunflower oil placebo, medium-chain triglyceride 
      oil placebo. Up to 10 escalating doses of the oils were planned for 
      administration via oral gavage, with at least 3 days separating doses. Clinical 
      observations, physical examinations, complete blood counts, clinical chemistry, 
      and plasma cannabinoids were used to assess safety, tolerability, and the 
      occurrence of adverse events (AEs). AEs were rated as mild, moderate, or 
      severe/medically significant. Results: Dose escalation of the CBD-predominant oil 
      formulation was shown to be as safe as placebo and safer than dose escalation of 
      oils containing THC (CBD/THC oil or THC oil). The placebo oils were delivered up 
      to 10 escalating volumes, the CBD oil up to the tenth dose (640.5 mg; ~62 mg/kg), 
      the THC oil up to the tenth dose (597.6 mg; ~49 mg/kg), and the CBD/THC oil up to 
      the fifth dose (140.8/96.6 mg CBD/THC; ~12 mg/kg CBD + 8 mg/kg THC). AEs were 
      reported in all dogs across the five groups and the majority (94.9%) were mild. 
      Moderate AEs (4.4% of all AEs) and severe/medically significant AEs (0.8% of all 
      AEs) manifested as constitutional (lethargy, hypothermia) or neurological 
      (ataxia) symptoms and mainly occurred across the two groups receiving oils 
      containing THC (CBD/THC oil or THC oil). Conclusions and clinical significance: 
      Overall, dogs tolerated dose escalation of the CBD oil well, experiencing only 
      mild AEs. The favorable safety profile of 10 escalating doses of a CBD oil 
      containing 18.3-640.5 mg CBD per dose (~2-62 mg/kg) provides comparative evidence 
      that, at our investigated doses, a CBD-predominant oil formulation was safer and 
      more tolerated in dogs than oil formulations containing higher concentrations of 
      THC.
CI  - Copyright (c) 2020 Vaughn, Kulpa and Paulionis.
FAU - Vaughn, Dana
AU  - Vaughn D
AD  - Canopy Animal Health, Canopy Growth Corporation, Toronto, ON, Canada.
FAU - Kulpa, Justyna
AU  - Kulpa J
AD  - Canopy Animal Health, Canopy Growth Corporation, Toronto, ON, Canada.
FAU - Paulionis, Lina
AU  - Paulionis L
AD  - Canopy Animal Health, Canopy Growth Corporation, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200211
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7029731
OTO - NOTNLM
OT  - CBD-cannabidiol
OT  - THC-tetrahydrocannabinol
OT  - adverse events
OT  - canine
OT  - cannabinoids
OT  - safety
EDAT- 2020/03/03 06:00
MHDA- 2020/03/03 06:01
PMCR- 2020/01/01
CRDT- 2020/03/03 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/03/03 06:00 [entrez]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2020/03/03 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fvets.2020.00051 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Feb 11;7:51. doi: 10.3389/fvets.2020.00051. eCollection 2020.